Everspin (MRAM) Q2 2026 earnings review
Massive Revenue Beat Overshadowed by Exploding Litigation Costs
Everspin delivered a blowout top-line quarter, with $18.7M in revenue absolutely shattering its prior guidance of $15.5-16.5M. This accelerating growth (+42% YoY) marks a decisive breakout from the $13-15M plateau of the last four quarters, driven by an impressive $15.3M in core product sales and initial execution of the $40M US prime contractor deal. However, the GAAP bottom line tells a completely different story. Net loss cratered to $(3.6)M as litigation expenses ballooned to $4.0M for the quarter. While Non-GAAP metrics look healthy (54.7% gross margin, $2.9M net income), the widening gap between GAAP and Non-GAAP profitability is a major red flag that investors cannot ignore. Guidance for Q3 suggests the revenue momentum is sustainable ($20M midpoint), but cash flow and GAAP earnings will remain under severe pressure.
🐂 Bull Case
After a year of stagnant mid-teens revenue, Everspin is accelerating fast. Q2 revenue grew 42% YoY, and Q3 guidance implies another ~42% YoY growth. The $40M US Defense contract is finally manifesting in the P&L.
The top-line beat wasn't just lumpy licensing revenue. MRAM product sales surged 38% YoY to $15.3M, proving solid end-market demand for PERSYST and Toggle MRAM products in industrial and aerospace applications.
🐻 Bear Case
Patent litigation costs jumped from $1.6M in Q1 to $4.0M in Q2. Management previously guided for costs 'in that range' (meaning Q1's $1.6M). This massive unforeseen spike obliterated GAAP profitability and severely damages management's forecasting credibility on legal spend.
Despite record revenue, Operating Cash Flow for 1H26 collapsed to just $0.7M (down from $6.5M in 1H25). The cash burn from litigation and working capital build is consuming the benefits of top-line growth.
⚖️ Verdict: ⚪
Neutral. The top-line acceleration and margin execution are incredibly impressive, proving the underlying MRAM technology demand. However, the unquantifiable and escalating litigation costs make it impossible to give a definitively bullish grade until cash flow normalizes.
Key Themes
GAAP vs. Non-GAAP OpEx Chasm
A massive divergence has opened between Everspin's reported (GAAP) operating expenses and its adjusted metrics. GAAP OpEx skyrocketed 66% YoY to $14.5M, driven by $4.0M in litigation costs and $1.05M in Non-recurring Engineering (NRE) fees related to the Microchip foundry agreement. Meanwhile, Non-GAAP OpEx sits at a very manageable $8.2M. While the company excludes these items to show operational health, investors must treat the legal cash drain as a highly material headwind that directly contradicts the 'record quarter' narrative.
Execution on the $40M US Defense Contract
The $40M prime contractor deal announced last quarter has begun to yield tangible results. Licensing, royalty, and other revenue surged to $3.4M in Q2, up from just $0.8M in Q1 and $2.1M a year ago. This confirms that Everspin is successfully hitting early milestones and recognizing high-margin, non-product revenue from this critical 2.5-year engagement.
Core Product Sales Breakout
MRAM product sales are accelerating dramatically, hitting $15.3M (up 38% YoY and up from $14.1M sequentially). This growth signifies that Everspin's strategy of expanding design wins across PERSYST and Toggle product lines is converting into volume shipments, moving the company past the cyclical inventory digestion seen in prior periods.
Macro Resilience in Key Verticals
Management explicitly cited strength in Industrial Automation, Energy Management, and Aerospace & Defense end markets. The resurgence in Industrial Automation is particularly notable, suggesting that the inventory normalization headwinds that plagued the sector in late 2025 and early 2026 are fully resolved.
Cash Flow and CapEx Pressures
Everspin reported only $0.7M in operating cash flow for the first six months of 2026, a steep decline from $6.5M in the same period last year. Simultaneously, capital expenditures (property and equipment) nearly doubled to $5.7M for 1H26 as the company invests in the Chandler facility and the new Microchip foundry line. Free cash flow has turned deeply negative, pulling total cash down slightly to $43.9M.
Gross Margin Leverage
Despite taking on initial work for the $40M defense contract and dealing with broader semiconductor volatility, Non-GAAP gross margin improved by 2.2 points YoY to 54.7%. This demonstrates strong pricing power for MRAM in mission-critical applications and excellent volume leverage through their manufacturing footprint.
Other KPIs
Accelerating. Up from 51.3% a year ago and 52.7% last quarter. The margin expansion confirms that higher top-line volumes are generating healthy factory utilization and favorable product mix, keeping the company well above its historical 50% target.
A newly reported line item excluded from Non-GAAP results, tied to the Microchip foundry agreement. This indicates that while the partnership is vital for domestic supply chain resilience, the upfront costs to establish the 10-year manufacturing line are now hitting the P&L.
Guidance
Accelerating. At the midpoint ($20.0M), this implies ~42% YoY growth compared to Q3 2025's $14.1M. This confirms that the Q2 beat was not a one-off pull-forward, but rather a structural step-up in the company's revenue run rate.
Stable. The midpoint of $0.125 represents consistent underlying operational profitability, hovering near the $0.11 delivered in Q2.
Reversing slightly from the deep Q2 loss, but remaining negative. The persistent gap between this metric and the Non-GAAP EPS guidance explicitly signals that management expects heavy litigation costs to continue burning cash in Q3.
Key Questions
Litigation Cost Visibility
Litigation costs spiked dramatically from $1.6M in Q1 to $4.0M in Q2. Are we at peak run-rate for these legal expenses, or should investors brace for $4M+ per quarter until the dispute is resolved?
Revenue Shape of the $40M Contract
With the massive top-line beat in Q2 and $20M midpoint guidance for Q3, how much of this step-up is driven by the cadence of milestones for the $40M US prime contractor deal versus baseline product sales growth?
NRE Fee Recurrence
You backed out $1.05M in NRE fees related to the Microchip foundry agreement this quarter. Should we expect a similar level of NRE exclusions in Q3 and beyond, or was this a one-time setup cost?
Path to Positive Cash Flow
Given the negative operating cash flow generation year-to-date and elevated CapEx requirements for the Microchip facility, at what revenue run-rate do you expect the company to return to sustainable positive free cash flow, inclusive of litigation costs?